{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:09:34Z","timestamp":1783087774201,"version":"3.54.6"},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Status epilepticus (SE) is a neurological emergency that requires timely pharmacological therapy to cease seizure activity. The treatment approach varies based on the time and the treatment stage of SE. Benzodiazepines are considered the first-line therapy during the emergent treatment phase of SE. Antiseizure medicines such as phenytoin, valproic acid, and levetiracetam are recommended during the urgent treatment phase. These drugs appear to have a similar safety and efficacy profile, and individualized therapy should be chosen based on patient characteristics. Midazolam, propofol, pentobarbital, and ketamine are continuous intravenous infusions of anesthetic medications utilized in the refractory SE (RSE) period. The most efficacious pharmacotherapeutic treatments for RSE and superrefractory status epilepticus are not clearly defined.<\/jats:p>","DOI":"10.1055\/s-0044-1785503","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T23:53:10Z","timestamp":1712361190000},"page":"324-332","source":"Crossref","is-referenced-by-count":2,"title":["Status Epilepticus: An Update on Pharmacological Management"],"prefix":"10.1055","volume":"44","author":[{"given":"Sulaiman","family":"Almohaish","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Clinical Pharmacy College, King Faisal University, Al-Ahsa, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eljim P.","family":"Tesoro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen M.","family":"Brophy","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clinph.2014.05.037","article-title":"The probability of seizures during EEG monitoring in critically ill adults","volume":"126","author":"M B Westover","year":"2015","journal-title":"Clin Neurophysiol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"R S Fisher","year":"2005","journal-title":"Epilepsia"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"E Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"I E Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"G M Brophy","year":"2012","journal-title":"Neurocrit Care"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"T Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3390\/jcm10081754","article-title":"Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines","volume":"10","author":"S Almohaish","year":"2021","journal-title":"J Clin Med"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"R Silbergleit","year":"2012","journal-title":"N Engl J Med"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/epi.16825","article-title":"Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial","volume":"62","author":"A G Sathe","year":"2021","journal-title":"Epilepsia"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1684\/epd.2018.0987","article-title":"Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus","volume":"20","author":"S K Rao","year":"2018","journal-title":"Epileptic Disord"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/epi.13056","article-title":"Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison","volume":"56","author":"V Alvarez","year":"2015","journal-title":"Epilepsia"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"e3203","DOI":"10.1212\/WNL.0000000000010913","article-title":"Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus","volume":"95","author":"E L Guterman","year":"2020","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.eplepsyres.2016.02.006","article-title":"Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis","volume":"122","author":"P Jain","year":"2016","journal-title":"Epilepsy Res"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archpediatrics.2010.130","article-title":"Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy","volume":"164","author":"M Holsti","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1097\/MD.0000000000000555","article-title":"Comparison of intranasal and intravenous diazepam on status epilepticus in stroke patients: a retrospective cohort study","volume":"94","author":"R Inokuchi","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"J Kapur","year":"2019","journal-title":"N Engl J Med"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12028-019-00708-5","article-title":"Safety and tolerability of rapid administration undiluted levetiracetam","volume":"32","author":"O Morgan","year":"2020","journal-title":"Neurocrit Care"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s12028-021-01237-w","article-title":"Evaluation of time to administration, benzodiazepine use, and safety of intravenous push levetiracetam in a neuro-spine intensive care unit","volume":"35","author":"T Adams","year":"2021","journal-title":"Neurocrit Care"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ana.25249","article-title":"Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures","volume":"83","author":"A M Husain","year":"2018","journal-title":"Ann Neurol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/ane.13469","article-title":"Efficacy of lacosamide and phenytoin in status epilepticus: a systematic review","volume":"144","author":"P K Panda","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/phar.2760","article-title":"Levetiracetam-associated behavioral adverse events in neurocritical care patients","volume":"43","author":"M Strein","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.12.001","article-title":"Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response","volume":"149","author":"I Aicua-Rapun","year":"2019","journal-title":"Epilepsy Res"},{"issue":"08","key":"ref28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.16094","article-title":"Use of intravenous brivaracetam in status epilepticus: a multicenter registry","volume":"60","author":"E Santamarina","year":"2019","journal-title":"Epilepsia"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12028-018-0560-6","article-title":"Safety and efficiency of intravenous push lacosamide administration","volume":"29","author":"K E Davidson","year":"2018","journal-title":"Neurocrit Care"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S5189","article-title":"Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety","volume":"5","author":"C Kellinghaus","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/epi.16961","article-title":"Rapid administration of undiluted intravenous levetiracetam","volume":"62","author":"J T Haller","year":"2021","journal-title":"Epilepsia"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/phar.2687","article-title":"The safety of rapid infusion levetiracetam: a systematic review","volume":"42","author":"A Jense","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1528-1167.2007.00989.x","article-title":"Safety of rapid intravenous loading of valproate","volume":"48","author":"N A Limdi","year":"2007","journal-title":"Epilepsia"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamaneurol.2021.0520","article-title":"Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus","volume":"78","author":"E L Guterman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s13311-018-0640-5","article-title":"Treatment of refractory and super-refractory status epilepticus","volume":"15","author":"S Rai","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1528-1157.2002.28501.x","article-title":"Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review","volume":"43","author":"J Claassen","year":"2002","journal-title":"Epilepsia"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/cc13883","article-title":"Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study","volume":"18","author":"D Pugin","year":"2014","journal-title":"Crit Care"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12028-010-9445-z","article-title":"A randomized trial for the treatment of refractory status epilepticus","volume":"14","author":"A O Rossetti","year":"2011","journal-title":"Neurocrit Care"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2042098616659414","article-title":"Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus","volume":"7","author":"C R Newey","year":"2016","journal-title":"Ther Adv Drug Saf"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1592\/phco.28.2.250","article-title":"Propofol-related infusion syndrome in intensive care patients","volume":"28","author":"S M Corbett","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12883-019-1281-y","article-title":"Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus","volume":"19","author":"Q Zhang","year":"2019","journal-title":"BMC Neurol"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40263-018-0569-6","article-title":"Ketamine for refractory status epilepticus: a systematic review","volume":"32","author":"A Rosati","year":"2018","journal-title":"CNS Drugs"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s12028-023-01811-4","article-title":"Safety and Efficacy of Ketamine Without Intubation in the Management of Refractory Seizures: A Case Series","volume":"40","author":"L A Kimmons","year":"2024","journal-title":"Neurocrit Care"},{"issue":"08","key":"ref49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-020-00747-z","article-title":"Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: a systematic review","volume":"34","author":"L M Willems","year":"2020","journal-title":"CNS Drugs"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ane.13061","article-title":"Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain","volume":"139","author":"A Strzelczyk","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/phar.2229","article-title":"Use of newer anticonvulsants for the treatment of status epilepticus","volume":"39","author":"S Farrokh","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"107139","DOI":"10.1016\/j.yebeh.2020.107139","article-title":"Treatment of status epilepticus with zonisamide: a multicenter cohort study of 34 patients and review of literature","volume":"109","author":"K Hubert","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00134-016-4501-6","article-title":"What's new in refractory status epilepticus?","volume":"43","author":"S Legriel","year":"2017","journal-title":"Intensive Care Med"},{"issue":"09","key":"ref55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/epi.17343","article-title":"Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial","volume":"63","author":"H Vaitkevicius","year":"2022","journal-title":"Epilepsia"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.25008","article-title":"Brexanolone as adjunctive therapy in super-refractory status epilepticus","volume":"82","author":"E S Rosenthal","year":"2017","journal-title":"Ann Neurol"},{"issue":"11","key":"ref61","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/phar.2797","article-title":"Personalized antiseizure medication therapy in critically ill adult patients","volume":"43","author":"S Almohaish","year":"2023","journal-title":"Pharmacotherapy"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1785503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:48:00Z","timestamp":1730818080000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1785503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":46,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,6,19]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1785503","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}